Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | PPARA | Q07869 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.63 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.63 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203843 | 0.82 | TSHR (0.68) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL13293853 | 0.81 | TSHR (0.55) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL4542705 | 0.79 | TSHR (0.63) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL18885323 | 0.78 | TSHR (0.62) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL17299694 | 0.78 | TSHR (0.62) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL5266458 | 0.78 | TSHR (0.70) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| Gemfibrozil SCHEMBL4813 | 0.78 | PPARA (1.00) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL9481043 | 0.78 | PPARA (0.79) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| Gemfibrozil SCHEMBL20770039 | 0.78 | PPARA (1.00) | TSHRPPARACYP2C9CYP2C8TDP1 | |
| SCHEMBL12690944 | 0.78 | PPARA (0.79) | TSHRPPARACYP2C9CYP2C8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022722-B2 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-03-02 | — | — | US | disclosed |
| US-6958355-B2 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050075379-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2005-04-07 | — | — | US | disclosed |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2005-02-17 | — | — | US | disclosed |
| US-6768008-B2 | FOR THERAPY | ARYX THERAPEUTICS | 2004-07-27 | — | — | US | disclosed |
| EP-1430039-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | Aryx Therapeutics (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6680387-B2 | USING THIAZOLIDINONE COMPOUND | ARYX THERAPEUTICS | 2004-01-20 | — | — | US | disclosed |
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2003024943-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TSHR 2074/4885PPARA 305/4885CYP2C9 611/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TSHR 2074/4885PPARA 305/4885CYP2C9 611/4885 |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TSHR 2074/4885PPARA 305/4885CYP2C9 611/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TSHR 2074/4885PPARA 305/4885CYP2C9 611/4885 |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TSHR 2074/4885PPARA 305/4885CYP2C9 611/4885 |
| US-20050075379-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TSHR 2074/4885PPARA 305/4885CYP2C9 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.